Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human continuous IV AMG 330 in myeloid malignancies
jRCT2071210044Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2015
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of eluvixtamab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (5 arms), sponsored by Amgen. Primary endpoints: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) and Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE). Started Aug 2015; status: completed.
02
Drugs
eluvixtamab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2071210044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210044.